New drug duo aims to tame High-Risk MDS

NCT ID NCT03564873

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs—omacetaxine and azacitidine—given together to people with untreated high-grade myelodysplastic syndromes (MDS), a serious bone marrow condition. The first part finds the safest dose of omacetaxine, and the second part checks how many patients achieve remission. About 28 adults will take part, receiving the drugs for 7 days each month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omacetaxine and azacitidine
What this could lead to: If successful, this combination could offer a new treatment option for people with high-grade myelodysplastic syndromes, potentially improving remission rates.
What could go wrong: This is a small, early-phase trial (Phase 1/2) with only 28 participants, so results may not apply broadly. The drugs can cause side effects like low blood counts and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Universtiy of Colorado Denver

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.